The 2022 European Heart Journal review offers a comprehensive overview of the application of anti-interleukin-1 (IL-1) agents in the management of recurrent pericarditis. The review discusses three primary anti-IL-1 agents—anakinra, rilonacept, and canakinumab—emphasizing their mechanisms and therapeutic roles. Anakinra, a recombinant human IL-1 receptor antagonist, and rilonacept, a fusion protein that acts as a soluble decoy receptor for IL-1a and IL-1b, have demonstrated significant efficacy and safety in patients who are corticosteroid-dependent and colchicine-resistant. Through randomized controlled trials and observational studies, these agents have significantly reduced the incidence of pericarditis recurrences, with minimal severe side effects and common adverse events like injection site reactions being well-tolerated by patients. The paper outlines the historical progression and clinical trials that have validated the use of anti-IL-1 agents, particularly focusing on anakinra and rilonacept. The authors detail findings from various studies, including the AIRTRIP and RHAPSODY trials, which demonstrated that both agents substantially lowered the recurrence rates of pericarditis when compared to placebo treatments. The methodological rigor of these trials, employing randomized, double-blind designs with extensive follow-up durations, provides robust support for the role of IL-1 inhibition in the therapeutic paradigm of recurrent pericarditis. The synthesis of these trials' outcomes, along with safety profiles characterized by low rates of serious adverse events, establishes anti-IL-1 agents as key advancements in managing this chronic and often refractory condition. Similarly, a 2022 systematic review and meta-analysis meticulously examined the therapeutic efficacy of rilonacept and anakinra in managing recurrent pericarditis, particularly in cases unresponsive to conventional therapies. The results from the systematic review highlighted the substantial benefits of anti-IL-1 therapy, with both rilonacept and anakinra significantly reducing the recurrence of pericarditis. The Phase III trial of rilonacept included in the analysis underscored its capacity to rapidly resolve acute episodes while decreasing the risk of recurrence, with marked improvements noted in quality of life and management of symptoms such as pain and inflammation. Similarly, evidence from studies on anakinra indicated its effectiveness as an alternative treatment for corticosteroid-dependent, recurrent pericarditis. The statistical analysis emphasized the superior odds ratios for therapeutic success with these agents, substantiating their role as viable options in refractory cases. Despite some limitations, including a relatively small number of RCTs, the review provides a compelling argument for incorporating anti-IL-1 therapies into the clinical management of recurrent pericarditis, emphasizing the need for further research in larger, diverse populations. [1], [2]
A 2021 review highlighted recent studies on the use of anti-IL-1 drugs, such as anakinra and rilonacept, in recurrent pericarditis. The RHAPSODY study, included in the review, focused on rilonacept, showing promising phase 3 results in terms of efficacy and safety. The increasing evidence supports the use of anti-IL-1 agents in patients with recurrent pericarditis and a significant inflammatory phenotype, indicating a shift towards more tailored therapeutic approaches in managing this condition. According to the 2021 review, the pathogenesis of recurrent pericarditis is linked to both adaptive and innate immune reactions, potentially triggered by infectious or environmental factors in genetically susceptible individuals. The study highlighted that in autoimmune pericarditis, viral infections can initiate autoimmune responses through molecular mimicry. Similarly, autoinflammatory pericarditis involves the innate immune system, with diseases like familial Mediterranean fever (FMF) and tumor necrosis factor receptor-associated periodic syndrome (TRAPS) shedding light on the role of inflammasome activation and IL-1 overproduction. These insights underline the potential of targeting IL-1 with specific inhibitors as a promising treatment avenue, offering relief for patients suffering from recurrent pericarditis when traditional therapies prove inadequate. [3]
A 2024 review delves into the clinical utility of rilonacept for the treatment of recurrent pericarditis (RP), emphasizing its design, development, and therapeutic role. The review outlines the significant challenges faced in managing RP due to its unpredictable relapses and the limited efficacy of traditional treatments like NSAIDs, glucocorticoids, and colchicine. The paper highlights that a breakthrough in this therapeutic area was achieved by targeting the inflammatory pathways, specifically the IL-1 cytokine, given its crucial role in the pathophysiology of pericarditis. The advent of IL-1 inhibitors, particularly rilonacept, marks a paradigm shift in treating RP resistant to conventional therapies. Rilonacept is described as a dimeric fusion protein that acts as a soluble decoy receptor, binding to IL-1α and IL-1β, thus inhibiting their inflammatory cascade. Its pharmacokinetic profile allows for weekly dosing, enhancing patient adherence. The publication emphasizes that clinical trials such as RHAPSODY have provided robust evidence of rilonacept’s efficacy in reducing pericarditis recurrence. In this pivotal phase 3 trial, patients with recurrent pericarditis showed remarkable improvement in both the frequency and severity of recurrences, with a significant reduction in inflammatory markers like C-reactive protein (CRP). Rilonacept was shown to not only alleviate symptoms but also enable the safe withdrawal or tapering of other medications, like glucocorticoids, thereby reducing their associated side effects. The RHAPSODY trial reported a noteworthy risk reduction of recurrence, with the median time to first recurrence significantly extended in the rilonacept group compared to placebo. Adverse events were mostly mild, including injection site reactions and upper respiratory tract infections, underscoring the favorable safety profile of rilonacept. These findings collectively underline rilonacept as a promising treatment option for RP, offering an improved quality of life and a reduced healthcare burden associated with this challenging condition. [4]
A 2021 phase 3, double-blinded, placebo-controlled, multicenter randomized-withdrawal trial investigated the efficacy and safety of rilonacept in patients experiencing symptomatic recurrent pericarditis with elevated CRP levels despite conventional therapy. This trial enrolled a total of 86 patients, with 61 completing the run-in period and undergoing randomization. Participants received an initial subcutaneous dose of rilonacept 320 mg, followed by 160 mg weekly for 12 weeks. Responders were then randomized to continue rilonacept 160 mg weekly or switch to placebo. The primary endpoint focused on the recurrence of pericarditis, while secondary endpoints assessed clinical response, CRP normalization, and discontinuation of standard therapy in favor of rilonacept monotherapy. The study, with a mean participant age of 44.7 years and a predominantly idiopathic cause of pericarditis (85%), demonstrated a substantial reduction in recurrence rates of pericarditis in those receiving rilonacept compared to placebo (7% vs. 74%), with a hazard ratio of 0.04 (95% CI, 0.01 to 0.18; P<0.001). Rilonacept led to rapid resolution of acute symptoms, significantly reduced pain within a median of 5 days, and normalized CRP levels in 7 days. The median duration of treatment, including the run-in period, was 9 months. All patients initially on corticosteroids were tapered off effectively to rilonacept monotherapy within 8 weeks. Although four participants discontinued due to adverse events, the therapy was generally well-tolerated; injection-site reactions and upper respiratory tract infections were the most common side effects. These findings underscore rilonacept's potential as a safe, effective, and steroid-sparing option for patients suffering from recurrent pericarditis, marking a significant advancement in targeted therapy for this inflammatory condition. [5]